Clinical Director, Transplant Infectious Disease
Department of Medicine, Infectious Disease Division
Massachusetts General Hospital, Boston, USA
Camille Nelson Kotton, MD, FIDSA, FAST, is the clinical director of the Transplant and Immunocompromised Host Infectious Diseases Program in the Infectious Diseases Division at Massachusetts General Hospital, and an associate professor of medicine at Harvard Medical School in Boston, MA.
Dr Kotton’s clinical interests include cytomegalovirus, vaccines, donor-derived infections, zoonoses, and travel and tropical medicine in the transplant setting. She is a recent member of the CDC Advisory Committee on Immunization Practices (ACIP) and was involved in national decisions regarding COVID-19 and other vaccines with a focused on immunocompromised patients.
Dr Kotton has served as the chair of The Infectious Disease Community of Practice of The American Society of Transplantation. She has also served as the president of The Transplant Infectious Disease Section of The Transplantation Society and highlights of her time as president include the development of 3 versions of the international guidelines on CMV management after solid organ transplant, published in Transplantation, with a fourth version underway. She is the first transplant infectious disease specialist to be elected to the executive council of The Transplantation Society.
Topic 1
Julián de la Torre Cisneros - Immunoguided Discontinuation of Prophylaxis for Cytomegalovirus Disease in Kidney Transplant Recipients Treated With Antithymocyte Globulin: A Randomized Clinical Trial
Professor of Medicine, University Of Cordoba
Head Service of Infectious Diseases,
Reina Sofia University Hospital-Imibic
Cordoba, Spain
Julián de la Torre Cisneros is a specialist in Internal Medicine with a Ph.D infectology and a Research fellowship in Transplant Infectious Diseases by the University of Pittburgh, USA . He is currently Professor of Medicine (Infectious Diseases) at the University of Córdoba, Spain and Head of the Infectious Diseases Service at the Reina Sofía University Hospital (HURS). He is Principal Investigator of the Maimonides Institute for Biomedical Research of Córdoba (IMIBIC). His lines of research are infection in the transplant patient, nosocomial infection and appropriate use of antibiotics. He leads international research projects and has been the coordinator of the Spanish Network for Research in Infectious Pathology (REIPI), formely CIBERINFEC, in HURS. He is the author of more than 350 research articles indexed in Scopus (half as principal investigator), more than 180 have been published in first quartile journals, with 10,392 citations in documents and an H index of 59.
Topic 2
Jose O. Reusing Jr. - QuantiFERON-CMV as a Predictor of CMV Events During Preemptive Therapy in CMVseropositive Kidney Transplant Recipients
Medical Supervisor, Kidney Transplant Unit Hospital das Clínicas, University of São Paulo School of Medicine São Paulo, Brazil
José O Reusing Jr., MD, PhD, is an attendant nephrologist and Medical Supervisor of the Kidney Transplant Unit of Hospital das Clínicas, São Paulo, Brazil.
Topic 3
Martina Sester - Overview of CMV guidelines and immunodiagnostics
Professor of Transplant and Infection Immunology, Faculty of Medicine
Saarland University, Hamburg, Germany
Martina Sester, PhD, is a professor of immunology and director of the department of transplant and infection immunology at Saarland University, Germany. She specialized in T-cell immunology with relevance to graft rejection and clinically relevant pathogens with specific interest on immunology towards cytomegalovirus, other herpesviruses, BK polyomavirus, Mycobacterium tuberculosis, and more recently SARS-CoV-2. Her research focuses on basic understanding of antigen-specific immune regulation in immunocompromised patients, and on translational aspects of immunomonitoring of infectious complications, vaccine responses, and graft rejection. She is a member of national and international transplant societies and participated in national and international consensus conferences and guideline committees.